Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 7—July 2007
Research

Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci

Marion A. Kainer*Comments to Author , Rose A. Devasia*†, Timothy F. Jones*, Bryan P. Simmons‡, Kelley Melton‡, Susan Chow‡, Joyce Broyles‡, Kelly L. Moore*, Allen S. Craig*, and William Schaffner§
Author affiliations: *Tennessee Department of Health, Nashville, Tennessee, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ‡Methodist University Hospital, Memphis, Tennessee, USA; §Vanderbilt University School of Medicine, Nashville, Tennessee, USA;

Main Article

Figure 4

Linezolid (LZD) usage during 2001–2005 at hospital A, Tennessee. Use of oral and intravenous (IV) formulations is shown in defined daily doses (DDD)/1,000 patient days. Data for 2001 and 2005 do not include all 12 months (2001 includes data from October through December; 2005 includes data from January through February). ICU, intensive care unit.

Figure 4. Linezolid (LZD) usage during 2001–2005 at hospital A, Tennessee. Use of oral and intravenous (IV) formulations is shown in defined daily doses (DDD)/1,000 patient days. Data for 2001 and 2005 do not include all 12 months (2001 includes data from October through December; 2005 includes data from January through February). ICU, intensive care unit.

Main Article

Page created: June 21, 2010
Page updated: June 21, 2010
Page reviewed: June 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external